Financial Status - As of June 30, 2025, the company holds $117 million in cash, cash equivalents, and investments[8] - Approximately 123 million common shares are outstanding, with roughly 142 million fully diluted shares[8] CRB-701 (Next-Generation Nectin-4 Targeting ADC) - CRB-701 aims to reduce PADCEV®-associated toxicities and extend ADC half-life to reduce dosing frequency[11] - CRB-701 has a precise and stable DAR of 2, leading to a longer half-life, improved binding affinity, and selectivity, resulting in a 2x rate of internalization compared to PADCEV®[14] - In a patient-derived tumor model, CRB-701 demonstrated a 745% reduction in mean tumor volume compared to PADCEV®, with p<005[18] - CRB-701 shows lower levels of free MMAE compared to PADCEV®; at a matched MMAE dose, CRB-701 had 35% Cmax and 38% AUC 0-21d of free MMAE compared to PADCEV®[20] - In HNSCC patients, CRB-701 at 36 mg/kg showed an ORR of 476% (10/21) and a DCR of 619%[41] - In cervical cancer patients, CRB-701 at 36 mg/kg showed an ORR of 375% (6/16) and a DCR of 688%[59] - In mUC patients, CRB-701 at 36 mg/kg showed an ORR of 556% (5/9) and a DCR of 889%[69] CRB-913 (Oral Cannabinoid Type-1 Inverse Agonist) - CRB-913 is designed as a best-in-class next-generation CB1 inverse agonist with higher peripheral restriction compared to monlunabant or rimonabant[86, 89] - At a dose of 10 mg/kg, CRB-913 has a brain:plasma AUC ratio of 1:50, compared to 1:5 for monlunabant and 1:1 for rimonabant[91] Upcoming Milestones - Clinical data readouts are expected for all three drug candidates (CRB-701, CRB-913, CRB-601) in the second half of 2025[7]